GlassScriptPhysician profile
Martha M Rodriguez
NPI 1508963802
$4,951.29
in general payments reported to CMS, 2019-2025
29 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,127 · 2020: $717 · 2021: $787 · 2022: $677 · 2023: $486 · 2024: $19.17 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,042.35 | 2019-2025 | Aveir, Freestyle Libre 3 |
| Amgen INC. | $423.41 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $359.30 | 2019-2022 | |
| Pfizer INC. | $278.53 | 2019-2023 | |
| Astellas Pharma US INC | $250.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $219.38 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $148.57 | 2019-2022 | |
| Relievant Medsystems, INC. | $140.77 | 2023 | Intracept |
| Gt Medical Technologies, INC | $123.05 | 2023 | Gammatile |
| Boston Scientific Corporation | $120.29 | 2021 | |
| Lilly USA, LLC | $115.38 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $95.12 | 2020-2022 | |
| Orthofix Medical, INC. | $92.86 | 2023 | Spinal-Stim, Spinal-Stim |
| Novartis Pharmaceuticals Corporation | $82.64 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $72.59 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $63.17 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $36.09 | 2021 | |
| Dexcom, INC. | $35.61 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.25 | 2019 | |
| Merck Sharp & Dohme LLC | $31.18 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $28.09 | 2023 | Jynarque |
| Biohaven Pharmaceutical Holding Company LTD. | $27.10 | 2022 | |
| Esperion Therapeutics, INC. | $23.52 | 2021 | |
| Edwards Lifesciences Corporation | $23.12 | 2021 | |
| Corcept Therapeutics | $22.67 | 2023 | Korlym |
| Mannkind Corporation | $19.16 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.54 | 2021 | |
| Currax Pharmaceuticals LLC | $13.25 | 2020 | |
| Eisai INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.